Nature Search

Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

Zhou et. al. report the interim results of the randomized phase III GEMSTONE-302 trial, showing the overall survival benefits of first-line treatment with the PD-L1 inhibitor sugemalimab versus placebo in combination with chemotherapy, in patients with NSCLC.

Caicun Zhou
Ziping Wang
Jason Yang
Research15 Jun 2023
Nature Cancer

Volume: 4, P: 860-871
Publisher Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

Caicun Zhou
Ziping Wang
Jason Yang
Amendments and Corrections05 Jan 2024
Nature Cancer

Volume: 5, P: 209
Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial

Yunpeng Yang
Jie Min
Wenfeng Fang
ResearchOpen Access14 Aug 2023
Signal Transduction and Targeted Therapy

Volume: 8, P: 1-8
Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial

Shun Lu
Hongming Pan
Jiajia Zhu
ResearchOpen Access30 Jun 2023
Signal Transduction and Targeted Therapy

Volume: 8, P: 1-11
Suberoylanilide Hydroxamic Acid Treatment Reveals Crosstalks among Proteome, Ubiquitylome and Acetylome in Non-Small Cell Lung Cancer A549 Cell Line

Quan Wu
Zhongyi Cheng
Pingsheng Fan
ResearchOpen Access31 Mar 2015
Scientific Reports

Volume: 5, P: 1-11

Quick links

Search

Filter By:

Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

Publisher Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial

Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial

Suberoylanilide Hydroxamic Acid Treatment Reveals Crosstalks among Proteome, Ubiquitylome and Acetylome in Non-Small Cell Lung Cancer A549 Cell Line

Search

Quick links